Vasant Narasimhan became the Chief Executive Officer of pharmaceuticals company Novartis on Thursday February 1, 2018. Prior to that, he was Global Head of Drug Development and Chief Medical Officer at the company. He was also Global Head of Development for Novartis Pharmaceuticals, Head of Biosimilars and Inoculable Cancer Medicines at Sandoz, Global Head of Development at Novartis Vaccines, Region Head, Novartis Vaccines North America and United States Country President of Novartis Vaccines and Diagnostics. Prior to joining Novartis in 2005, Vasant Narasimhan worked for McKinsey & Company.
Dr. Narasimhan received his medical degree from Harvard Medical School in the US, a master’s degree in public policy from Harvard’s John F. Kennedy School of Government, and a bachelor’s degree in biological sciences from the University of Chicago in the US. During and after his medical studies, he worked extensively on a range of public health issues in developing countries. He is an elected member of the US National Academy of Medicine and serves on the board of fellows of Harvard Medical School.
Aged 41, Vasant is the son of Indian immigrants from Tamil Nadu, India, his mother is a former nuclear engineer for Public Service Electric and Gas and his father was a researcher at Hoeganaes Corporation.
Novartis posts strong 2017 results
on 24th January 2017, Novartis CEO Joe Jimenez announced fourth quarter and full year 2017 results. In his remarks Jimenez said: “It was a landmark year for innovation resulting in a rich late-stage pipeline. With several key launches on the horizon and our new operating model in place, Novartis is poised for sustainable growth.”
Vas Narasimhan, said : “I want to thank Joe and the Board for their leadership and guidance as I transition to my new role. I feel privileged to lead Novartis at this exciting time.”